Buscar
Mostrando ítems 11-14 de 14
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: extended follow-up of the coBRIM study
(American Association for Cancer Research, 2021)
Purpose: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer
(Nature publishing group, 2021)
Identifcation of the diferent elements intervening at the tumor microenvironment seems key to explain clinical evolution in several tumor types. In this study, a set of immune biomarkers (myeloid derived suppressor ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
(MDPI, 2021-10-29)
The PANGEA-Breast trial evaluated a new chemo-immunotherapeutic combination that would synergistically induce long-term clinical benefit in HER2-negative advanced breast cancer patients. Treatment consisted of 21-day cycles ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
![Premio Mensual Publicación Científica Destacada de la US. Facultad de Medicina Icon](/themes/idUS/images/certificate.png)
Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial
(MDPI, 2021-09-15)
The search of prognostic factors is a priority in diffuse large B-cell lymphoma (DLBCL) due to its aggressiveness. We have recently found that the level of circulating MDSCs is a good marker of survival in a translational ...